EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Macrophage Activator GcMAF‐RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming

Vera S Ruzanova iD, Svetlana S Kirikovich iD, Evgeniy V Levites iD, Anastasia S Proskurina iD, Evgeniya V Dolgova iD, Genrikh S Ritter iD, Yaroslav R Efremov iD, Tatyana D Dubatolova iD, Alexander V Sysoev iD, Danil I Koleno iD, Alexandr A Ostanin iD, Elena R Chernykh iD und 1 weitere

Journal of Immunology Research · 2024

DOI: 10.1155/2024/7484490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, 2024. Verfasst von Vera S Ruzanova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. Hauptthemen laut MEDLINE: Macrophages, Neoplasms, Vitamin D-Binding Protein, Macrophage-Activating Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inga N. Zaitseva, Russian Ministry of Science and High Education via the Institute of Cytology and Genetics, “ACTIVATOR MAF” LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophages are the immune cells of high‐immunological plasticity, which can exert both pro‐ and anti‐inflammatory activity, as well as repolarize their phenotype to the opposite or neutral one. In this regard, M2 macrophages of the tumor‐associated stroma (TAS) are a promising therapeutic target in treating malignant neoplasms. Using FACS assay, we have estimated the CD11b+/Ly‐6G+/Ly‐6C+ fraction of macrophages from the peritoneum and TAS in intact healthy mice and those with developed Lewis carcinoma, both untreated and treated according to Karanahan technology in combination with group‐specific macrophage activator (GcMAF‐RF). As well, the pattern of pro‐ and anti‐inflammatory cytokines mRNA expression in different groups of experimental and tumor‐bearing animals was assessed. It was found that: (i) exposure of intact mice to GcMAF‐RF results in the increased number of CD11b+/Ly‐6C+ peritoneal macrophages and, at the same time, the expression pattern of cytokines in peritoneal macrophages switches from that characteristic of the mixed M1/M2 phenotype to that characteristic of the neutral M0 one; (ii) combination of Karanahan technology and GcMAF‐RF treatment results in M0/M1 repolarization of TAS macrophages; (iii) in tumor‐bearing mice, the response of peritoneal macrophages to such a treatment is associated with the induction of anti‐inflammatory reaction, which is opposite to that in TAS macrophages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesNeoplasmsVitamin D-Binding ProteinMacrophage-Activating FactorsMiceAnimalsMacrophages, PeritonealCytokinesAnti-Inflammatory Agents

Substanzen

vitamin D-binding protein-macrophage activating factorCytokinesAnti-Inflammatory AgentsVitamin D-Binding ProteinMacrophage-Activating Factors

Autor:innen und Institutionen

  • Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
  • Novosibirsk National Research State University, Novosibirsk, Russia.
  • Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
  • N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
  • Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.

ORCID-Profile: Vera S Ruzanova, Svetlana S Kirikovich, Evgeniy V Levites, Anastasia S Proskurina, Evgeniya V Dolgova, Genrikh S Ritter, Yaroslav R Efremov, Tatyana D Dubatolova, Alexander V Sysoev, Danil I Koleno, Alexandr A Ostanin, Elena R Chernykh, Sergey S Bogachev

Förderung

  • Inga N. Zaitseva
  • Russian Ministry of Science and High Education via the Institute of Cytology and Genetics
  • “ACTIVATOR MAF” LLC

Zitieren

APA

Ruzanova, V. S., Kirikovich, S. S., Levites, E. V., Proskurina, A. S., Dolgova, E. V., Ritter, G. S., Efremov, Y. R., Dubatolova, T. D., Sysoev, A. V., Koleno, D. I., Ostanin, A. A., Chernykh, E. R., & Bogachev, S. S. (2024). The Macrophage Activator GcMAF‐RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming. Journal of Immunology Research. https://doi.org/10.1155/2024/7484490

Vancouver

Ruzanova VS, Kirikovich SS, Levites EV, Proskurina AS, Dolgova EV, Ritter GS, et al. The Macrophage Activator GcMAF‐RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming. Journal of Immunology Research. 2024. doi:10.1155/2024/7484490

BibTeX
@article{Ruzanova2024,
  author = {Ruzanova, Vera S and Kirikovich, Svetlana S and Levites, Evgeniy V and Proskurina, Anastasia S and Dolgova, Evgeniya V and Ritter, Genrikh S and Efremov, Yaroslav R and Dubatolova, Tatyana D and Sysoev, Alexander V and Koleno, Danil I and Ostanin, Alexandr A and Chernykh, Elena R and Bogachev, Sergey S},
  title = {The Macrophage Activator GcMAF‐RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming},
  journal = {Journal of Immunology Research},
  year = {2024},
  doi = {10.1155/2024/7484490}
}
Kostenlos starten →